Ipsen hopes deal for Epizyme can unlock Tazverik’s commercial potential

Ipsen’s acquisition of Epizyme at a bargain price gives the French pharma an opportunity to boost sales of a cancer drug that has fallen short of the biotech’s expectations, as it has yet to capture a substantial portion of a market with multibillion-dollar potential.

For $1.45 per share, or $247 million up front, Ipsen Group (Euronext:IPN; PINK:IPSEY) will purchase 15-year-old Epizyme Inc. (NASDAQ:EPZM), an epigenetics pioneer whose first drug, Tazverik tazemetostat, first gained approval in 2020...